ML-DS 2018
Phase III clinical trial with CPX-351 in children with Down syndrome 2018
Myeloid leukaemia is a rare form of blood cancer in children and adolescents and affects the entire body. Children with Down syndrome have a greatly increased risk of developing myeloid leukaemia. Although they have a better prognosis than children without Down syndrome, these patients are more susceptible to the side effects of intensive chemotherapy. For these reasons, a specialised treatment for children with ML-DS is necessary. The aim of this study is to assess whether introducing the new medication Vyxeos can reduce side effects without compromising the chances of cure. The study investigates how children respond to this treatment and what side effects they experience. The dose of the medication will also be reduced towards the end of treatment for children who have responded well to chemotherapy in order to minimise side effects. Based on positive data from previous international studies, this treatment is expected to lead to a similar survival rate while greatly reducing both acute and long-term side effects.
Is this study suitable for my child’s condition?
Leukaemia, lymphoma and bone marrow disease
- Acute lymphoblastic leukemia (ALL)
- Acute myeloid leukemia (AML)
- Chronic myeloid leukemia (CML)
- Myelodysplastic syndrome (MDS)
- Severe aplastic anemia (SAA)
- Non-Hodgkin lymphoma
- Hodgkin lymphoma
- Other leukaemia, lymphoma and bone marrow disease
Brain and spinal cord tumors
- Low-grade glioma
- High-grade glioma
- Diffuse-intrinsic pontine glioma (DIPG) / Diffuse midline glioma (DMG)
- Medulloblastoma
- Atypical teratoid rhabdoid tumours (ATRT)
- Ependymoma
- Germ cell tumours / germinoma / nongerminomatous germ cell tumours / teratoma (brain / spinal cord)
- Craniopharyngioma
- Other brain tumours or spinal cord tumours
Solid tumors
- Wilms tumours / nephroblastoma
- Neuroblastoma
- Rhabdomyosarcoma
- Ewing sarcoma
- Osteosarcoma
- Rhabdoid tumours (other than brain or spinal cord)
- Other sarcoma
- Germ cell tumours (other than brain or spinal cord)
- Retinoblastoma
- Hepatoblastoma
- Other solid tumours
Study Information
What age range of children can participate?
Up to 6 years
Official Study Information
Questions? Please contact your medical team.
If you would like more information about a study, please speak to your child’s treating physician. They are your primary point of contact and can provide personalized advice and support. If no treatment team is currently in place, you can find general contact information for the study sites on the map below.
Treatment Centers with Open Study – Map & Overview
The map shows all treatment sites in Switzerland. Locations where the study is currently open are marked in blue. You can find contact details by clicking on the towns. The information on study sites is updated regularly. However, a study may occasionally open at a new site before this is reflected on the platform. If in doubt, please contact your treatment team or one of the listed clinics directly.
Basel
Universitäts-Kinderspital beider Basel UKBB
Spitalstrasse 33
4056 Basel
+41 61 704 12 12
www.ukbb.ch
Bern
Inselspital, Universitätsspital Bern
Kinderklinik
Julie-von-Jenner-Haus
Freiburgstrasse 15
3010 Bern
Telefon: +41 31 632 04 61
https://kinderklinik.insel.ch/de/unser-angebot/onkologie/
Sekretariat Hämatonkologie
Telefon: +41 31 632 04 61
E-Mail: kinder.haematonkologie@insel.ch
Genève
HUG Hôpitaux Universitaires Genève
Département de la Femme, de l’Enfant et Adolescent (DFEA)
Service de Pédiatrie Générale
Hôpital des Enfants
Rue Willy-Donzé 6
1205 Genève
Téléphone: +41 22 372 40 00
https://enfants-ados.hug.ch/hopital-enfants
https://www.hug.ch/departement-femme-enfant-ado/services-medicaux
Unité d’Oncologie et Hématologie Pédiatrique (UOHP)
Téléphone: +41 22 372 47 31
https://enfants-ados.hug.ch/specialites-medicales-chirurgicales/oncologie-hematologie-pediatrique
Plateforme de recherche CANSEARCH en Oncologie et Hématologie pédiatrique,
Département de Pédiatrie, Gynécologie et Obstétrique
Université de Genève
Centre Médical
Téléphone: +41 79 553 61 00
Email : plateforme-cansearch@unige.ch
https://www.unige.ch/medecine/petri/groupes-de-recherche/907ansari
Lausanne
CHUV Centre Hospitalier Universitaire Vaudois
Service de pédiatrie – Département femme-mère-enfant
Hôpital des Enfants CHUV
Rue du Bugnon 50
1011 Lausanne
https://www.chuv.ch
Unité d’hématologie-oncologie pédiatrique (HOP)
Main phone : +41 21 314 35 90
Email: ped.pon@chuv.ch
https://www.chuv.ch/fr/dfme/dfme-home/enfants-famille/specialites-medicales/hematologie-oncologie-pediatrique/oncologie-pediatrique
Luzern
Luzerner Kantonsspital
Kinderspital Zentralschweiz
Haus 33
Spitalstrasse
6000 Luzern 16
Telefon: +41 41 205 31 66
https://www.luks.ch/standorte/standort-luzern/kinderspital/leistungsangebot-kinderspital/boesartige-erkrankungen-tumoren-bluterkrankungen-bei-kindern-und-jugendlichen
Kontakt Onkologie
Telefon: +41 41 205 31 86
kinderspital.ambi2west@luks.ch
St. Gallen
Stiftung Ostschweizer Kinderspital
Zentrum für Onkologie/ Hämatologie
Claudiusstrasse 6
9006 St. Gallen
https://www.kispisg.ch/de/fachbereiche/kompetenzen/onkologie
Telefon : + 41 71 243 70 43
Email: info.Onkologie-CRC@kispisg.ch
Zürich
Universitäts-Kinderspital Zürich –
Eleonorenstiftung
Lenggstrasse 30
8008 Zürich
https://www.kispi.uzh.ch
Sekretariat Onkologie
Telefon: +41 44 249 63 50
E-Mail: onkologie.sekretariat@kispi.uzh.ch